Gilead Sciences
$65.179876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$65.17
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.01 (+0.02%) Today
+$0.12 (+0.18%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!
About GILD
Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Employees
11,800
Headquarters
Foster City, California
Founded
1987
Market Cap
81.55B
Price-Earnings Ratio
—
Dividend Yield
4.03
Average Volume
10.47M
High Today
$65.17
Low Today
$64.05
Open Price
$64.95
Volume
14.26M
52 Week High
$85.97
52 Week Low
$60.89
Collections
GILD News
MarketWatchSep 15
The M&A surge: Is it rational exuberance or a frenzy before the market falls?
The M&A surge: Is it rational exuberance or a frenzy before the market falls? More
The rise in equity markets and low funding costs encouraged chief executives
Analyst Ratings
37%
of 30 ratings
Buy
37%
Hold
57%
Sell
7%
GILD Earnings
$0.00
$0.61
$1.21
$1.82
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
— per share
Actual
Expected Oct 22, After Hours
More GILD News
ReutersSep 14
Gilead's shares rise after $21 billion deal for Immunomedics
(Reuters) - Shares of Gilead Sciences Inc <GILD.O> rose 3.2% on Monday, reversing their premarket losses as investors shrugged off concerns over the steep premi
BloombergSep 14
Gilead Ramps Up Cancer Focus With $21 Billion Immunomedics Deal
(Bloomberg) -- Gilead Sciences Inc. agreed to acquire Immunomedics Inc. for about $21 billion, a substantial premium for the maker of a promising breast-cancer
Yahoo FinanceSep 14
Gilead Sciences to acquire Immunomedics in $21B deal
Gilead Sciences is set to acquire Immunomedics in a $21 billion dollar deal, which is expected to close in the fourth quarter of 2020. Dr. Behzad Aghazadeh, Imm
CNBCSep 14
Gilead CEO: We're studying new ways to treat coronavirus with remdesivir outside of the hospital
Gilead Sciences CEO Daniel O'Day told CNBC on Monday the company is continuing to study new ways to use its coronavirus treatment remdesivir on patients, includ
